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Abstract
Although in vitro anchorage-independent growth is
widely used as a marker of cell transformation, the
biological implications of this trait are poorly under-
stood. We previously demonstrated that enforced an-
chorage-independent growth of a nontumorigenic, im-
( )mortalized epithelial cell line IEC-18 in multicellular
spheroid culture results in massive apoptotic cell death.
This death process, termed anoikis, is prevented by
expression of transforming oncogenes, which also con-
fer tumorigenic competence. This study examines
whether acquisition of an anoikis-resistant phenotype
is causally related to the tumorigenic capacity of trans-
formed epithelial cells. Parental IEC-18 cells were sub-
jected to 10 cycles of selection for survival in speroid
culture. Unlike parental cells, the resulting anoikis-re-
( )sistant variants AR1.10 and AR2.10 formed relatively
large tumors in nude mice. Both anoikis-resistant sub-
lines displayed upregulated expression of vascular en-
( )dothelial growth factor VEGF , a potent angiogenesis
stimulator. VEGF121 overexpression alone did not in-
duce tumorigenic conversion of parental IEC-18 cells,
which remained highly susceptible to anoikis. We pos-
tulate that both anoikis-resistance and angiogenic-com-
petence contribute to tumor formation. Development of
anoikis-resistance can be then viewed as a precondi-
tion for expression of the tumorigenic phenotype. Our
results suggest that even when angiogenesis is not a
( )rate limiting factor e.g. in vitro the selective pressures
of solid tumor–like, 3-dimensional growth conditions
favoring anoikis resistance result in collateral induction
of a proangiogenic phenotype.
Keywords: anoikis, angiogenesis, tumor progression, intestinal epithelium, VEGF,
apoptosis.
Introduction
Anchorage-independent growth, discovered almost 35 years
ago, remains a widely accepted in vitro hallmark and surro-
gate marker of malignant transformation and tumorigenesis
[ ]1,2 . Indeed, the distinct ability of tumor cells to grow in
semisolid media, suspension or multicellular spheroid cul-
ture has been frequently linked to aberrant cellular mitogen-
[ ]esis, i.e., anchorage-independent growth 3 , and more
recently, to abnormal control of physiologic cell death pro-
[ ]cesses, i.e., anchorage independent survival 4,5 . The
latter is of particular importance for epithelial cells, for which
attachment to basement membranes and proper uni- or
multilayered cytoarchitecture appear to be an important cell
survival mechanism. Withdrawal or disruption of such a
survival signal, e.g., by placing epithelial cells in 3-dimen-
sional culture, is associated with precipitous induction of
what is currently known as adhesion regulated programmed
( ) [ ]cell death ARPCD 6 or death of homelessness, for
[ ]which the term anoikis has been coined recently 7 . Anoikis
is believed to act as an essential safeguard mechanism that
helps maintain proper cell number, geographic architecture,
and position in epithelial organs. It is not entirely clear how
this form of apoptosis is executed and controlled.
Some recent molecular analyses have implicated activation
( )of c-jun terminal kinase JNK1 , MEKK, and caspase 8
[ ]8 . However, some of these results have also been
[ ]disputed 9 .
Anoikis can be aborted, or mitigated, by overexpression
of proto-oncogenic proteins, such as Bcl-2 or v-Src, or by
[ ]mutant oncogenes, such as H-ras 6 . The latter type of
cellular transformation is now known to exert this survival
function through activation of phosphoinositol 3XOH kinase
( ) ( ) [ ]PI3K and protein kinase B PKB/Akt 11 a pathway that
can change the phosphorylation status of some apoptosis-
[ ]effector genes, such as BAD 12 or expression levels of
[ ]others, such as BAK 13 . It is likely that some of these
genetic and signaling changes may be relevant for anchor-
age-independent growth and in vivo survival of cells derived
from spontaneous tumors, as well as for the ability of single
cancer cells or small aggregates to survive in the blood-
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stream or in ectopic organ sites after extravasation. How-
ever poorly understood, the molecular defects underlying
anchorage independence in general, and resistance to
anoikis in particular, appear to be quite heterogenous, even
within tumors of the same origin. For example, somatic
gene knockout studies have demonstrated that inactivation
of the mutant K-ras allele reproducibly leads to a marked
decrease in soft agar colony formation by 2 independent
[ ]colorectal cancer cell lines 14 . Although this finding sug-
gests that oncogenic ras may be essential for abnormal
[ ]3-dimensional growth capacity 14 , it is also true that K-ras
mutations are detected in only about 50% of colorectal
carcinoma cases and in a proportion of the respective
cancer cell lines in culture, whereas virtually all such cell
lines are capable of some degree of anchorage indepen-
dent growth and survival. It is therefore possible that resis-
tance to anoikis may represent a generic phenotype that is
strongly selected for, regardless of whether tumor progres-
(sion is driven by one particular molecular pathway e.g.,
)activating ras mutations or another.
Despite the strong correlation between the resistance of
transformed cells to anoikis and their ability to form tumors
in vivo, direct evidence for a causal relationship between
the two characteristics has not been firmly established. This
is because available cancer cells usually express a multi-
tude of functional abnormalities such as resistance to vari-
ous apoptosis-inducing stimuli, deregulated mitogenic activ-
ity, reduced growth requirements, and expression of proan-
giogenic properties, all of which are difficult to separate
functionally from each other. Indeed, different aspects of the
transformed phenotype may become rate limiting at differ-
ent stages of tumor growth and progression. For example,
anoikis would probably severely limit early stages of 3-di-
mensional expansion of tumor cells because they would be
forced to lose their contact with the basement membrane,
whereas angiogenesis would be required at later times to
allow tumor growth beyond the microscopic size of 1 to 2
[ ]mm in diameter 15,16 .
In order to elucidate some of these interrelationships in a
more direct manner, we designed an in vitro selection
protocol, which theoretically would specifically favor the
acquisition of resistance of epithelial cells to anoikis. For
( )this purpose, we used an immortalized but nontumorigenic
rat intestinal epithelial cell line, IEC-18, which displays some
intrinsic heterogeneity as to the kinetics of cell death in-
duced under anchorage-independent growth conditions in
spheroid culture. We showed that sequential exposure of
IEC-18 cells to such 3-dimensional culture conditions spon-
taneously leads to the derivation of rare cellular variants
with a markedly reduced susceptibility to anoikis. This expo-
sure was also sufficient for acquisition of tumorigenic com-
petence by these cells in vivo and was associated with the
collateral and spontaneous upregulation of VEGF, a potent
stimulator of angiogenesis. These observations raise the
possibility that during epithelial tumorigenesis, selective
pressures exerted by 3-dimensional growth conditions may
favor survival pathways, the activation of which is coupled
with the simultaneous ability to induce tumor angiogenesis.
Materials and Methods
Cells and Culture Conditions
IEC-18 cells were obtained and cultured as described
[ ]previously 6 . Briefly, all cell lines were maintained in mono-
layer culture in growth medium containing aMEM base
(supplemented with 5% fetal bovine serum Gibco BRL,
)Gaithersburg, MD , 4 mmol/L L-glutamine, 20 mmol/L glu-
(cose, 10 mg/mL insulin, Sigma Chemical Co, St. Louis,
)MO . VEGF overexpressing cell lines were generated by121
transfection of IEC-18 cells with the pcDNAI expression
vector containing the respective cDNA coding sequence by
( )using a lipofectin reagent Gibco BRL , as indicated by the
manufacturer. Transfectants 18V1 and 18V7, expressing
various amounts of VEGF , were selected in 400 mg/mL121
( )of G418 Gibco BRL and periodically exposed to the drug
afterward. For selection of cells in spheroid culture,
single-cell suspensions were prepared and plated at a con-
centration of 1–2=105 cells per well in 24 well plates
( )Nunc, Denmark precoated with a thin layer of 1%
( )Seaplaque agarose FMC Corp, Rockland, ME . After 4 to 7
( )days of incubation longer for later selections the mostly
dead and dying IEC-18 cells contained in the 24 wells were
( )transferred to a 100-mm Nunc tissue culture dish and left
to recover in the regular growth medium. After the surviving
clones were expanded, the cells were plated again in
agarose-coated dishes, and the cycle was repeated 9 times.
Cell Survival Assays
The characteristics of apoptotic death of IEC-18 cells in
spheroid culture, its abrogation in oncogenic ras transfec-
( )tants e.g., the ras-3 and ras-4 clones of IEC-18 , have
[ ]been described in detail 6 . For the purpose of the present
study we have used a commercially available version of the
( )MTS assay Promega, Madison, WI to evaluate cumulative
cell survival. Briefly, the cells were plated in spheroid culture
at 104 per well of the 96 well plate precoated with 2%
( ) ( )poly 2-hydroxyethyl methacrylate Sigma . At the time
points indicated, 100 mL of a mixture containing MTS,
( )phenazine methosulfate Promega, Madison, WI , reagent,
( )and Hank’s balanced salt solution 300:15:700 was added
to the wells and the absorbance at 490 nm recorded after 1
and 3.5 hours. The average absorbance from multiple wells
containing spheroids was normalized to absorbance of cor-
responding monolayer cultures or to day zero in time course
experiments. Similar conditions were used to estimate the
rate of apoptotic cell death by using Cell Death Elisa Plus
( )assay Boehringer Mannheim Canada, Laval, Quebec ,
which quantitates nucleosomes released into the cytoplasm
of dying cells. In this case cells were collected from multiple
spheroid-containing wells, lysed and incubated with a mix-
ture of biotinylated antihistone antibody and peroxidase-con-
jugated anti-DNA antibody, both of which bind to histon-DNA
complexes and initiate color reaction in the presence of the
X [ ]ABTS 2,2 -Azino-di 3-ethylbenzthiazolin-sulfonat substrate
( )Boehringer Mannheim Canada, Laval, Quebec . The OD
reading at 405 nm was corrected according to negative
control and expressed as an enrichment factor, according to
Neoplasia v Vol. 1, No. 1, April 1999
Anoikis and Angiogenesis Rak et al. 25
the manufacturer’s instruction. In spheroid culture the inten-
sity of this reaction peaked between 24 and 72 hours, with
some variation between the cell lines and under the influ-
(ence of culture conditions e.g., confluence before plating
)could also influence the results . For H-ras–transformed
cells and monolayer cultures the reaction only becomes,
( )positive at later time points after day 4 as a function of cell
density and depletion of the media.
Tumorigenicity Assay
Single-cell suspensions of all cell lines indicated were
prepared from monolayer cultures and 2–5=106 cells were
(injected subcutaneously into BALB/c nu/nu mice Taconic,
)Germantown, NY . Tumors were measured weekly and their
( 2volume calculated according to the standard formula: a =
)b /2, where a is the width and b is the length of the
horizontal tumor perimeter. The animals were sacrificed
before any visible signs of discomfort were present accord-
ing to the guidelines of the Animal Care Commitee at
Sunnybrook Health Science Centre.
Detection of VEGF by Northern Analysis
Total cellular RNA was extracted by using Trizol reagent
( )according to the manufacturer’s instructions Gibco BRL .
The samples were resolved on 1% agarose gel, and the
equal loading was verified by staining with ethidium bromide
( ) ( )EtBr . RNA was then transferred to Hybond N q mem-
( )brane Amersham Canada, Oakville, Ontario which was
hybridized with VEGF, cDNA, or GAPDH cDNA probes, as
[ ]described previously 10 . All cell lines expressing VEGF
mRNA were also positive for VEGF protein, which was
secreted into their conditioned medium and detected by
(antimouse VEGF antibody for ras-3, ras-4, AR1.10, AR2.10
) ( )cells and antihuman VEGF antibody 18V1 and 18V7 with
( )Quantakine Elisa Kits R&D Systems Inc, Minneapolis, MN .
Data Analysis
All tests were repeated at least 2 to 3 times with similar
results. The numerical data were presented as average
values, with error bars representing standard deviations.
Results
Derivation of Spontaneous Anoikis-Resistant Variants
IEC-18 cells were originally established from embryonic
( )rat intestinal crypt epithelium. They are known to be highly
[ ]sensitive to anoikis 6 . Thus, the cells do not form colonies
[ ]in soft agar 17 and undergo massive apoptosis when
( )forced to grow in a tumor-like fashion as large 1 mm ,
[ ] ( )multicellular spheroids 6 on nonadhesive agarose-coated
dishes. During this death process, a proportion of the cells
initially form a tight aggregate while remaining cells disinte-
(grate outside the spheroid, forming a halo of debris Figure
)1B . Because we have previously observed some degree of
heterogeneity between different IEC-18 derived clones with
respect to their sensitivity to cell death in spheroid culture,
we reasoned that cryptic subpopulations that are relatively
resistant to anoikis might exist, and that such cells may be
( )selected and/or further induced by long-term growth as
spheroids. To test this hypothesis, IEC-18 cells were sub-
jected to repeated cycles of selection for survival and growth
( )in spheroid culture Figure 1A . After each 4- to 7-day
incubation period on agarose-coated dishes, the remnants
of IEC-18 spheroids were collected from several wells,
plated in monolayer culture, and left to recover for several
weeks. The few clones that survived were expanded and
plated in another round of spheroid culture. After 10 cycles
of such selection we observed that the resulting cellular
variants obtained were capable of forming larger spheroids
( )Figure 1B composed of cells that indeed displayed a
reduced rate of cell death, albeit to a lesser extent than, for
example, sublines of IEC-18 overexpressing a mutant H-ras
( )oncogene Figure 1C . Two such anoikis-resistant variants,
designated AR1.10 and AR2.10, each derived in an inde-
pendent series of selections, were found to be stable in that
their survival properties in spheroid culture were retained
even after several weeks of prior growth as standard mono-
layer cultures.
Selection for Anoikis Resistance in Vitro Cosegregates with
a Tumorigenic Phenotype in Vivo
Our prior experience with the parental IEC-18 cells have
shown that these cells are absolutely nontumorigenic after
subcutaneous injection into nude mice, regardless of cell
( 6)number in the inoculum 1–5=10 or the duration of the
( )follow up time up to 12 months . Even the presence of
Matrigel in the inoculum, which has been shown to signifi-
cantly increase tumorigenic competence of immortalized
[ ]fibroblasts 18 , was unable to render the IEC-18 cells
( )tumorigenic unpublished observations . In contrast, as we
have shown previously, expression of the mutant H-ras
oncogene had a pleiotropic transforming effect on IEC-18
(cells manifested by exuberant tumorigenic properties com-
)pare respective tumor takes and growth rates in Figure 2A
that were attributed to the combination of effects this onco-
gene has on the ability of the cells to survive, proliferate,
and induce an effective angiogenic response under 3-di-
[ ]mensional growth conditions in vivo 6,10,19 . However, the
relative contribution of each of these changes has not been
formally examined. In this regard, K-ras–dependent upregu-
lation of VEGF and associated angiogenic capacity appear
to be necessary, but not sufficient, for expression of a
tumorigenic phenotype by human colorectal cancer cells
[ ]20 . Furthermore, the inability of immortalized epithelial
cells to form tumors in vivo in some cases may be over-
( )come at least to a small degree solely by increasing their
angiogenic competence, e.g., by transfection-mediated
[ ]overexpression of VEGF 21 . Such a manipulation was
clearly ineffective when applied to IEC-18 cells. Thus, trans-
( )fected IEC-18 cells overexpressing human VEGF 18V7121
at levels comparable to those observed in the aforemen-
( )tioned H-ras transfectants Figure 2B completely failed to
form tumors, even after injection of as many as 5=106
( )cells Figure 2A . This is consistent with the notion that such
VEGF transfectants would in theory remain susceptible to
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( )Figure 1. Derivation of anoikis-resistant variants of IEC-18 cells. A. Experimental protocol see text . B. Morphology of
(spheroids composed of IEC-18, AR1.10, AR2.10 or ras-3 cells after 48 hours in 3-dimensional culture. Original magnifica-
) ( )tion =100 C. Cumulative survival curves MTS assay of anoikis resistant variants of IEC-18 cells derived by spheroid
( ) ( )selection protocol AR1.10, AR2.10 or transformation with mutant H-ras oncogene ras-4 .
( )Figure 1. continued .
anoikis and thus die regardless of and prior to generation of
new blood vessels. Indeed, growth of the VEGF overex-
pressing 18V7 IEC-18 cells in spheroid culture resulted in a
similar degree of apoptosis to the parental IEC-18 cell line
as measured by nucleosomal release to the cytoplasm
( )apoptotic enrichment factor and low cumulative survival
( ) ( )capacity MTS assay Figure 3 .
Surprisingly, selection for anoikis resistance alone re-
sulted in acquisition of a tumorigenic phenotype by both
( )AR1.10 and AR2.10 cell lines see Figure 2 . Injection of
2=106 cells of each variant resulted in formation of
slow-growing tumors in 9 of 10 and 5 of 8 mice, respec-
tively. Despite their slow growth, the tumors eventually
reached considerable sizes, e.g., 500 to 2000 mm3, within 4
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Figure 2. Tumor - forming capacity of IEC -18 variant cell lines.
IEC-18— parental cells; 18V1 and 18V7— IEC-18 cells transfected
with the human VEGF ; AR1.10 and AR2.10—anoikis- resistant vari-121
ants selected for survival in spheroid culture; ras-3 and ras-4— IEC-18
cells transfected with mutant H- ras oncogene. A. Tumor growth kinetics
( 6in nude mice AR1.10, AR2.10, ras-3, ras-4— 2=10 per inoculum;
6 )remaining cells— 5=10 per inoculum . Three independent series of
injections were carried out with both AR1.10 and AR2.10 cell lines as
well as appropriate IEC-18 controls. In each case the results were
highly reproducible in that no tumors resulted from IEC-18 injections
while the variants were consistently tumorigenic. Mice were monitored
(for at least 4 months, and even up to 12 months e.g., the IEC-18
)injections . The data pooled from two such experiments are presented.
B. Expression of hVEGF by transfected IEC -18 cell lines, total RNA121
Northern blot.
to 5 months. Cell lines reisolated from some of these tumors
( )AR2T1 and AR2T2 were even more resistant to anoikis in
spheroid culture and morphologically indistinguishable from
( )their parental AR2.10 cell line Figure 3 and data not shown .
Variants Selected for Resistance to Anoikis Constitutively
Upregulate VEGF
The observation that injection of AR1.10 and AR2.10
cells in nude mice leads to formation of solid tumors that
expand beyond 1 to 2 mm in diameter suggested that,
Figure 3. Survival properties of IEC -18 derived tumorigenic vari-
ants in spheroid culture. Cumulative cell survival after 3 days in
( ) ( )spheroid culture MTS assay . Inset Rate of nucleosomal release
( )apoptotic enrichment factor as measured after 48 hours in spheroid
( )culture by Cell Death Elisa assay see text .
unlike the parental IEC-18 cells, the anoikis-resistant vari-
ants are able to mount an angiogenic response in vivo. This
(suggests the possibility of a functional link between resis-
) ( )tance to anoikis and induction of angiogenesis. To evalu-
ate this possibility, we decided to examine the anoikis-re-
sistant variants for their expression of VEGF. We did so for
3 reasons. First, parental IEC-18 cells are known to be
[ ]VEGF negative 10 . Second, VEGF is a potent proangio-
[ ]genic regulator 22 . Third, high levels of VEGF are induced
in other transformed and tumorigenic sublines of IEC-18
[ ]cells 10 . Indeed, testing for VEGF expression revealed a
several-fold constitutive upregulation of the transcript in
( )both anoikis-resistant cell lines tested Figure 4 . This up-
regulation was not as pronounced as in the case of mutant
( )ras-transformed IEC-18 cells ras-3 . Nevertheless, the lev-
els of VEGF corresponded well with the respective degrees
of both tumorigenicity and anoikis resistance in both vari-
Figure 4. Upregulation of VEGF mRNA expression in anoikis - re-
sistant cell lines selected in spheroid culture. IEC -18— parental
cells; AR1.10 and AR2.10—spontaneously derived anoikis- resistant
variants of IEC-18; ras-4— IEC-18 cells transfected with mutant H- ras.
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(ants of IEC-18 cells selected in spheroid culture see Figure
)2 and Figure 3 .
Discussion
Two findings are presented in this article. First, an unbiased
selection of immortalized epithelial cells for resistance to
(anoikis in vitro confers a tumorigenic albeit relatively
)low-grade phenotype in vivo, and second, that anoikis
resistance and tumor angiogenesis may be functionally cou-
pled and thereby coselected during tumor progression. The
first finding could shed new light on the significance of
anchorage-independent growth. Thus, the ability to grow as
colonies in soft agar remains perhaps the most consistent
in vitro correlate of the in vivo tumorigenic phenotype
[ ]1,2,23 . By growing cells as large multicellular aggregates
on a thin layer of agarose, rather than as relatively inacces-
sible single cells or very small clonal colonies within soft
agar, we were able to select for and recover variant subpop-
ulations having the competence to grow as anchorage-inde-
pendent multicellular spheroids. To our knowledge this is
the first demonstration that intentional selection for ability to
grow as anchorage independent entities not only correlates
with tumorigenicity but can actually directly contribute to this
phenotype.
The second finding, namely, a possible link between
anoikis resistance and tumor angiogenesis, is implied by the
first finding because progressive tumorigenic growth in vivo
cannot proceed in the absence of induction of angiogenesis
[ ]24 . In this regard, the ability of the anoikis-resistant vari-
ants to produce spontaneously VEGF could obviously con-
tribute to induction of the angiogenic response in vivo,
although induction of other angiogenesis effectors as well
[ ]as loss of endogenous inhibitors could also be involved 25 .
These possibilities are currently being studied in more de-
tail.
Our results may be pertinent to the factors that govern
the angiogenic switch in developing tumors and to the
question of when this switch actually begins to take place.
Although there may be instances of a chronic avascular
phase responsible for keeping tumors microscopic and dor-
mant, evidence is accumulating that the angiogenic switch
can occur at very early stages of tumor progression, i.e.,
during the premalignant phases of tumor development in
[ ]some types of cancer 26 . For example, in 3 different
transgenic mouse models of tumorigenesis involving forma-
tion of pancreatic carcinomas, squamous cell carcinomas,
and fibrosarcomas, the angiogenic switch was found to
occur in the various precursor lesions before overt tumor
[ ]formation 26 . Similarly, there is evidence that in human
cancers in which the early stage precursor lesions can be
identified, angiogenesis can be detected as early as in the
[ ]horizontal growth phase of primary melanomas 27 , in
[ ]cervical dysplasias 28 , and in similar lesions associated
[ ]with the mammary duct 26 . In these situations, the ability
of transformed cells to grow and survive as a multicellular
mass rather than as a sheet or monolayer of cells resting on
a basement membrane implies some degree of resistance
( )to anoikis, and this, in turn as suggested by our results ,
may contribute to ability of the surviving cells to trigger
angiogenesis. Clearly, other factors could contribute to this
[ ]switch as well, e.g., hypoxia 29 and/or additional genetic
[ ]alterations 25 . This possibility is consistent with the
low-grade tumorigenic phenotype of the anoikis-resistant
sublines of IEC-18 cells.
Whereas the molecular mechanisms of tumor angiogene-
sis, and specifically the role of VEGF, are becoming increas-
ingly better defined, it is not clear how the angiogenic
phenotype is actually selected for. Such a phenotype per se
would be expected to provide a relatively weak selective
advantage because new blood vessels may be shared by
both angiogenically competent and angiogenically incompe-
[ ]tent tumor cell populations 30 . In this regard, it is important
to note that genetic lesions implicated in triggering tumor
angiogenesis, such as activating mutations of the ras
proto-oncogene or inactivating mutations of p53, are also
known to render tumor cells resistant to apoptosis-inducing
[ ]stimuli 6,31 . Hence, it is possible that strong selection
pressures favoring the latter property facilitate dominance of
tumor cell clones which are at the same time angiogenically
competent. The pleiotropic phenotypes of AR1.10 and
AR2.10 cell lines seem to suggest such a possibility in the
context of anoikis. A corollary to this discussion might be
that at the later stages of tumor progression at least some
(of the genetic changes involved e.g., p53 mutations in
)colon cancer may not only trigger a more aggressive
proangiogenic phenotype, but also simultaneously reduce
cellular susceptibility to undergo apoptosis under microenvi-
( ) [ ]ronmental stress conditions such as hypoxia 31 and in
doing so, double their impact on tumor growth by effectively
lowering the relative dependency of tumors cells on the
[ ]blood supply 32 .
The molecular basis of the anoikis-resistant–like pheno-
type in the AR-IEC-18 sublines is unknown. It is possible
that this phenotype is reflective of some degree of cryptic
spontaneous transformation that occurred during the long
period that IEC-18 cells were maintained in monolayer tis-
sue culture. A considerable number of candidates for trans-
forming genes that could confer such a phenotype have
already been identified by previous gene transfection stud-
ies. Mutant H- and K-ras have been shown to abrogate
[ ] (anoikis in IEC-18 cells 6,33 , as have v-src our unpub-
) ( ) [ ]lished observation , integrin-linked kinase ILK 34 and
[ ] (BCL-2 6 . With the exception of BCL-2 our unpublished
)observation , transfection of these transforming oncogenes
was found to result in the simultaneous expression of a
tumorigenic and angiogenic phenotype.
Although the molecular pathways responsible for simulta-
neous induction of anoikis resistance and upregulation of
VEGF remain unknown, we believe that a valuable lesson
can be drawn from the studies on human counterparts of
the IEC-18 system that are currently being developed. This
is because the method of selection in 3-dimensional culture
used in our experimentation is fairly objective and not de-
pendent on the preconceptions usually associated with
transfection of a specific transforming gene into a recipient
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nontumorigenic cell line. This strategy also has a potential
for gene expression cloning and comparative gene expres-
sion analysis, both of which can be used for unbiased
identification of genes involved in early stages of progres-
sion of colorectal cancer, breast cancer, and other epithelial
human malignancies derived from cell types naturally sus-
ceptible to anoikis. It can be speculated that in colorectal
cancer such candidate genes could include the mutant APC
tumor suppressor gene and the K-ras oncogene, because
both of these genetic changes are frequently found at rela-
[ ]tively early stages of disease progression 35 ; moreover,
[ ]both have been linked to regulation of cell survival 6,36 .
Finally, growth of the anoikis resistant IEC-18 variant
sublines as tumors in vivo further increased their ability to
( )survive in the 3-dimensional culture Figure 3 . This is
indicative of the cumulative and quantitative nature of anoikis
resistance in which various secondary changes inflicted on
the cells during their tumorigenic growth in vivo may have
contributed to increasing survival capacity. Indeed, such
secondary changes may account for the acute acceleration
of tumor growth that was noticeable after first 3 to 4 months
after injection of the cells. Nevertheless, despite the large
sizes of tumors from which the AR2T1 and AR2T2 cell lines
were isolated, their resistance to anoikis was still consider-
ably lower than that of H-ras–transfected cells. This differ-
ence may reflect a distinct nature of the molecular defects
expressed by both AR2.10 derivatives.
In summary, two critical aspects of the transformed phe-
notype, namely resistance to anoikis and angiogenic com-
petence, may be functionally coupled, suggesting that se-
lection of cells for competence to grow 3-dimensionally
favors certain types of pleiotropic molecular defects rather
than simply cell survival in general. Therapeutic targeting of
such pleiotropic defects could be highly effective as it could
simultaneously suppress or obliterate multiple essential
components of the tumorigenic phenotype, such as tumor
( )angiogenesis and the apoptosis i.e. anoikis resistant phe-
notype of tumor cells.
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